On January 9, 2017, Immunomedics, Inc. announced a newly reconstituted Board of Directors and the implementation of a leadership succession plan. Furthermore, the Company stated that effective immediately, it has appointed 4 new independent directors: Jason Aryeh, Geoffrey Cox, Robert Forrester, and Bob Oliver. In addition, the Company announced that it has filed the supplement to the proxy statement with the Securities and Exchange Commission in connection with its upcoming annual meeting to stockholders unanimously recommending that they vote on the white proxy card for all 7 of the Company’s director nominees: Jason Aryeh, Geoffrey Cox, Robert Forrester, David M. Goldenberg, Brian A. Markison, Bob Oliver, and Cynthia L. Sullivan.